These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 8301579)
1. MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. Rollema H; Skolnik M; D'Engelbronner J; Igarashi K; Usuki E; Castagnoli N J Pharmacol Exp Ther; 1994 Jan; 268(1):380-7. PubMed ID: 8301579 [TBL] [Abstract][Full Text] [Related]
2. 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. Bloomquist J; King E; Wright A; Mytilineou C; Kimura K; Castagnoli K; Castagnoli N J Pharmacol Exp Ther; 1994 Aug; 270(2):822-30. PubMed ID: 8071874 [TBL] [Abstract][Full Text] [Related]
4. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. Giovanni A; Sonsalla PK; Heikkila RE J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148 [TBL] [Abstract][Full Text] [Related]
5. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147 [TBL] [Abstract][Full Text] [Related]
6. Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate. Matarredona ER; Santiago M; Machado A; Cano J Br J Pharmacol; 1997 Jul; 121(5):1038-44. PubMed ID: 9222565 [TBL] [Abstract][Full Text] [Related]
7. Brain extraction of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a neurotoxic metabolite of haloperidol: studies using [3H]HPP+. Kawashima H; Iida Y; Kitamura Y; Kiyono Y; Magata Y; Saji H Jpn J Pharmacol; 2002 Aug; 89(4):426-8. PubMed ID: 12233823 [TBL] [Abstract][Full Text] [Related]
8. Effect of MPTP on brain mitochondrial H2O2 and ATP production and on dopamine and DOPAC in the striatum. Fabre E; Monserrat J; Herrero A; Barja G; Leret ML J Physiol Biochem; 1999 Dec; 55(4):325-31. PubMed ID: 10731084 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. Staal RG; Sonsalla PK J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000 [TBL] [Abstract][Full Text] [Related]
10. Studies on the mechanism of the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Heikkila RE; Nicklas WJ; Duvoisin RC Adv Neurol; 1987; 45():149-52. PubMed ID: 3103384 [No Abstract] [Full Text] [Related]
11. Effect of a pyridinium metabolite derived from haloperidol on the activities of striatal tyrosine hydroxylase in freely moving rats. Igarashi K; Matsubara K; Kasuya F; Fukui M; Idzu T; Castagnoli N Neurosci Lett; 1996 Aug; 214(2-3):183-6. PubMed ID: 8878114 [TBL] [Abstract][Full Text] [Related]
12. Dopaminergic neurotoxicity of 1-methyl-4-phenylpyridinium analogs in cultured neurons: relationship to the dopamine uptake system and inhibition of mitochondrial respiration. Saporito MS; Heikkila RE; Youngster SK; Nicklas WJ; Geller HM J Pharmacol Exp Ther; 1992 Mar; 260(3):1400-9. PubMed ID: 1312170 [TBL] [Abstract][Full Text] [Related]
13. MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. Rollema H; Kuhr WG; Kranenborg G; De Vries J; Van den Berg C J Pharmacol Exp Ther; 1988 Jun; 245(3):858-66. PubMed ID: 2455037 [TBL] [Abstract][Full Text] [Related]
14. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters. Kang HJ; Lee SS; Lee CH; Shim JC; Shin HJ; Liu KH; Yoo MA; Shin JG Drug Metab Dispos; 2006 Jul; 34(7):1145-51. PubMed ID: 16624869 [TBL] [Abstract][Full Text] [Related]
15. Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins. Castagnoli N; Castagnoli KP; Van der Schyf CJ; Usuki E; Igarashi K; Steyn SJ; Riker RR Pol J Pharmacol; 1999; 51(1):31-8. PubMed ID: 10389142 [TBL] [Abstract][Full Text] [Related]
16. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats. Ablordeppey SY; Borne RF Pharmacol Biochem Behav; 1993 Nov; 46(3):739-44. PubMed ID: 8278454 [TBL] [Abstract][Full Text] [Related]
17. The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study. Foster SB; Wrona MZ; Han J; Dryhurst G Chem Res Toxicol; 2003 Oct; 16(10):1372-84. PubMed ID: 14565778 [TBL] [Abstract][Full Text] [Related]
18. Effects of a quaternary pyridinium metabolite of haloperidol (HP+) on the viability and catecholamine levels of cultured PC12 cells. Fang J; Yu PH Can J Physiol Pharmacol; 1997 Aug; 75(8):996-1000. PubMed ID: 9360014 [TBL] [Abstract][Full Text] [Related]
19. Tissue culture model for studying MPTP toxicity to dopamine neurons. Mytilineou C; Cohen G Adv Neurol; 1987; 45():145-8. PubMed ID: 3493622 [No Abstract] [Full Text] [Related]
20. Comparative toxicity of MPTP, MPP+ and 3,3-dimethyl-MPDP+ to dopaminergic neurons of the rat substantia nigra. Sayre LM; Arora PK; Iacofano LA; Harik SI Eur J Pharmacol; 1986 May; 124(1-2):171-4. PubMed ID: 3487462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]